[go: up one dir, main page]

EE200300363A - N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks - Google Patents

N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks

Info

Publication number
EE200300363A
EE200300363A EEP200300363A EEP200300363A EE200300363A EE 200300363 A EE200300363 A EE 200300363A EE P200300363 A EEP200300363 A EE P200300363A EE P200300363 A EEP200300363 A EE P200300363A EE 200300363 A EE200300363 A EE 200300363A
Authority
EE
Estonia
Prior art keywords
pyridinyl
indole
medicament
diseases
manufacture
Prior art date
Application number
EEP200300363A
Other languages
English (en)
Estonian (et)
Inventor
P. Smith Craig
P. Rathbone Michel
Petty Margaret
Rampe David
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of EE200300363A publication Critical patent/EE200300363A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300363A 2001-02-15 2002-02-14 N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks EE200300363A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number Publication Date
EE200300363A true EE200300363A (et) 2003-10-15

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300363A EE200300363A (et) 2001-02-15 2002-02-14 N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks

Country Status (39)

Country Link
US (10) US6967210B2 (xx)
EP (1) EP1368031A2 (xx)
JP (3) JP2004518711A (xx)
KR (3) KR100951540B1 (xx)
CN (2) CN1529598A (xx)
AP (1) AP1749A (xx)
AR (1) AR035750A1 (xx)
AU (3) AU2002247200B9 (xx)
BR (1) BR0207272A (xx)
CA (1) CA2438712A1 (xx)
CO (1) CO5390085A1 (xx)
CR (1) CR7023A (xx)
CZ (1) CZ20032172A3 (xx)
EA (2) EA011319B1 (xx)
EC (1) ECSP024218A (xx)
EE (1) EE200300363A (xx)
GB (1) GB0119435D0 (xx)
HK (1) HK1080361B (xx)
HR (1) HRP20030652A2 (xx)
HU (1) HUP0303203A3 (xx)
IL (2) IL157341A0 (xx)
MA (1) MA26152A1 (xx)
ME (1) MEP21208A (xx)
MX (1) MXPA03006110A (xx)
MY (1) MY157745A (xx)
NO (1) NO20033622L (xx)
NZ (4) NZ539159A (xx)
OA (1) OA12549A (xx)
PA (1) PA8540101A1 (xx)
PE (1) PE20040175A1 (xx)
PL (1) PL363638A1 (xx)
SG (1) SG134170A1 (xx)
SK (1) SK10392003A3 (xx)
TR (4) TR200301330T2 (xx)
TW (1) TWI325319B (xx)
UA (2) UA80394C2 (xx)
WO (1) WO2002064126A2 (xx)
YU (1) YU62903A (xx)
ZA (1) ZA200306124B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
CA2514581A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
WO2011118364A1 (en) * 2010-03-26 2011-09-29 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
US11730769B2 (en) 2017-12-22 2023-08-22 Children's Medical Center Corporation Compositions and methods for Williams Syndrome (WS) therapy
WO2022159086A1 (en) * 2021-01-20 2022-07-28 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
DE69016531T2 (de) * 1989-08-02 1995-07-06 Hoechst Roussel Pharma 2,3-Dihydro-1-(pyridinylamino)-indole, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel.
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
EP1056754B1 (en) * 1998-01-29 2003-10-22 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
US20050234105A1 (en) 2005-10-20
MA26152A1 (fr) 2004-07-01
HUP0303203A2 (hu) 2003-12-29
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
AU2002247200B2 (en) 2007-12-13
US20030105150A1 (en) 2003-06-05
US20090209594A1 (en) 2009-08-20
TR200800691T2 (tr) 2008-03-21
US20090281147A1 (en) 2009-11-12
CN1529598A (zh) 2004-09-15
AU2002247200B9 (en) 2008-07-10
JP2004518711A (ja) 2004-06-24
US20090209595A1 (en) 2009-08-20
US7230015B2 (en) 2007-06-12
WO2002064126A2 (en) 2002-08-22
YU62903A (sh) 2006-05-25
EA200600896A1 (ru) 2006-08-25
EA011319B1 (ru) 2009-02-27
KR20040014459A (ko) 2004-02-14
KR20090005254A (ko) 2009-01-12
EP1368031A2 (en) 2003-12-10
IL157341A0 (en) 2004-02-19
NZ556697A (en) 2009-01-31
CR7023A (es) 2003-11-17
HUP0303203A3 (en) 2007-11-28
TR200301330T2 (tr) 2004-12-21
US7179821B2 (en) 2007-02-20
CZ20032172A3 (cs) 2004-01-14
CO5390085A1 (es) 2004-04-30
IL157341A (en) 2010-11-30
WO2002064126A3 (en) 2003-02-20
NZ544720A (en) 2007-08-31
KR20090005255A (ko) 2009-01-12
KR100951542B1 (ko) 2010-04-09
UA80394C2 (en) 2007-09-25
ZA200306124B (en) 2004-11-08
OA12549A (en) 2006-06-05
US6967210B2 (en) 2005-11-22
CA2438712A1 (en) 2002-08-22
TR200800693T2 (tr) 2008-07-21
MEP21208A (en) 2010-06-10
HK1080361B (zh) 2009-10-30
AR035750A1 (es) 2004-07-07
US7534803B2 (en) 2009-05-19
SG134170A1 (en) 2007-08-29
US20050159456A1 (en) 2005-07-21
CN100522164C (zh) 2009-08-05
US20040157888A1 (en) 2004-08-12
UA88773C2 (ru) 2009-11-25
HRP20030652A2 (en) 2005-06-30
US20040157889A1 (en) 2004-08-12
US20060025452A1 (en) 2006-02-02
PL363638A1 (en) 2004-11-29
AU2009238332A1 (en) 2009-12-10
US20090270458A1 (en) 2009-10-29
PA8540101A1 (es) 2003-09-05
EA012409B1 (ru) 2009-10-30
CN1679564A (zh) 2005-10-12
HK1080361A1 (zh) 2006-04-28
AU2008201179A1 (en) 2008-04-03
NZ539159A (en) 2006-11-30
NO20033622D0 (no) 2003-08-14
ECSP024218A (es) 2003-09-24
EA200300882A1 (ru) 2003-12-25
NO20033622L (no) 2003-10-06
KR100951540B1 (ko) 2010-04-09
PE20040175A1 (es) 2004-03-29
MXPA03006110A (es) 2005-07-01
JP2009185045A (ja) 2009-08-20
GB0119435D0 (en) 2001-10-03
AU2008201179B2 (en) 2009-08-20
JP2010120958A (ja) 2010-06-03
AP2003002834A0 (en) 2003-09-30
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
AP1749A (en) 2007-06-13
BR0207272A (pt) 2004-02-10
NZ527011A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
EE200300363A (et) N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
EE200000253A (et) Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks
IL168279A (en) Use of liposomal and aminoglycoside composition to prepare a drug for the treatment or improvement of infection
DK1272207T3 (da) Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
EE200400029A (et) Kristalliline antikolinergikum, meetod selle valmistamiseks ja selle kasutamine ravimi valmistamiseks
ATE502635T1 (de) Kombinationstherapie gegen hyperproliferative erkrankungen
ATE359784T1 (de) Topische nasenbehandlung mit desloratadin und mometason furoat
EE200200062A (et) Monoaminoksüdaasi inhibiitorite kasutamine ravimite valmistamiseks rasvumuse raviks
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE05056B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
NO20023448L (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
EE200300139A (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
IL157144A0 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
SI1530462T1 (sl) 1-fenil-2-dimetilaminometicikloheksanske spojine za terapijo depresivnih simptomatik, bolečine in inkontinence
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks